Is DHCR7 rs12785878 GG linked to lower vitamin D status?

The DHCR7 gene regulates the precursor pool available for cutaneous vitamin D synthesis by encoding 7-dehydrocholesterol reductase. Genetic variations at this locus significantly influence circulating vitamin D levels, which in turn modulate systemic immune responses and upstream thyroid hormone transcription pathways.

Genetic and clinical evidence

• Genotypic impact: The G allele of the DHCR7 rs12785878 single nucleotide polymorphism is robustly associated with lower serum 25-hydroxyvitamin D [25(OH)D] levels.
• Insufficiency risk: Each copy of the G allele decreases circulating 25(OH)D by approximately 2 to 4 nmol/L (~1 ng/mL). Consequently, individuals carrying the homozygous GG genotype exhibit 30% to 40% higher odds of vitamin D insufficiency compared to TT carriers.

Immune and endocrine modulation

• Systemic-to-local conversion: Precursor 25(OH)D is converted locally into active calcitriol by the enzyme CYP27B1 within lymphoid and peripheral tissues.
• Immunotolerogenic signaling: Active calcitriol binds to the vitamin D receptor (VDR) and heterodimerizes with the retinoid X receptor (RXR). This genomic signaling shifts immune cell profiles away from pro-inflammatory lineages (Th1/Th17 cells, M1 macrophages) toward tolerogenic states (FoxP3-positive Treg cells, M2 macrophages) and suppresses inflammatory cytokines like IFN-γ and IL-17.

Mechanistic pathways of thyroid conversion

• Indirect transcriptional regulation: Vitamin D does not directly execute or enzymatically control the peripheral conversion of thyroxine (T4) to active triiodothyronine (T3).
• Deiodinase expression: Calcitriol-VDR signaling acts as an upstream genomic regulator that upregulates the transcription of type 2 deiodinase (DIO2). Lower vitamin D status leads to reduced DIO2 expression, restricting the outer-ring deiodination pathway that converts T4 into T3.

Bottom line

• Bottom line: The DHCR7 rs12785878 GG genotype predisposes individuals to lower circulating vitamin D, which compromises immunotolerogenic VDR-RXR signaling and indirectly impairs peripheral T4-to-T3 conversion by downregulating upstream DIO2 transcription.